Cost of a 5-year lung cancer survivor:symptomatic tumour identification vs proactive computed tomography screening

摘要

@@BACKGROUND:Our objective was to analyse the cost effectiveness of computed tomography (CT) screening for lung cancer in terms of the cost per long-term survivor,which has not been evaluated to date. Methods Estimations were computed based on data from the Surveillance,Epidemiology,and End Results registries covering years 1999-2003. The design framework of our model allowed for the incorporation of multiple values taken from the epidemiological and clinical literature to be utilised for cost inputs,scope of patients screened,diagnostic staging,and survival percentages applied separately to two cohorts:age 40-79 and 60-79 years. This enabled the analysis of over 1400 scenarios,each containing a unique set of input values,for which the estimated cost per 5-year survivor (CP5YS) was compared between the symptom-detected and proactive screening approaches.